Previous Close | 80.05 |
Open | 80.05 |
Bid | 80.02 x 800 |
Ask | 80.04 x 1100 |
Day's Range | 79.24 - 80.25 |
52 Week Range | 69.10 - 95.19 |
Volume | 920,047 |
Avg. Volume | 3,116,130 |
Market Cap | 40.932B |
Beta (5Y Monthly) | 0.65 |
PE Ratio (TTM) | 45.35 |
EPS (TTM) | 1.77 |
Earnings Date | Feb 04, 2021 |
Forward Dividend & Yield | 0.98 (1.19%) |
Ex-Dividend Date | Dec 03, 2020 |
1y Target Est | 93.56 |
Baxter's (BAX) BioPharma Solutions business inks deal to advance commercial-scale production and increase access for the COVID-19 vaccine in the U.K. and European markets.
Baxter BioPharma Solutions announced an agreement with Novavax to provide sterile manufacturing services for its COVID-19 vaccine candidate.
Baxter International Inc. (NYSE:BAX), a leading global medical products company, will host a conference call to discuss its fourth-quarter 2020 financial results on Thursday, February 4, 2021 at 7:30 a.m. Central Time. To participate in this conference call please follow this link http://www.directeventreg.com/registration/event/5044187 to pre-register for the call and receive the call information.